Skip to main content
Canna~Fangled Abstracts

Endocannabinoid System Attenuates Oxaliplatin-Induced Peripheral Sensory Neuropathy Through the Activation of CB1 Receptors

By November 18, 2021No Comments

Abstract

Oxaliplatin-induced neurotoxicity is expressed as a dose-limiting peripheral sensory neuropathy (PSN). Cannabinoid substances have been investigated for the analgesic effect. This study aimed to investigate the role of cannabinoid receptors in oxaliplatin-associated PSN. Swiss male mice received nine oxaliplatin injections (2 mg/kg, i.v.). Mechanical and thermal nociceptive tests were performed for 56 days. CB1, CB2, and c-Fos expression were assessed in dorsal root ganglia (DRG), spinal cord (SC), trigeminal ganglia (TG), spinal trigeminal nucleus caudalis (Sp5C), and periaqueductal gray (PAG). Iba-1 expression was assessed in DRG and ATF3 in TG. Cannabidiol (10 mg/kg, p.o.) or a CB1/CB2 non-selective agonist (WIN 55,212-2; 0.5 mg/kg, s.c.) or AM251 (CB1 antagonist) or AM630 (CB2 antagonist) (3 mg/kg, i.p.) were injected before oxaliplatin. Oxaliplatin increased CB1 in DRG, SC, TG, Sp5C, and ventrolateral PAG, with no interference in CB2 expression. Cannabidiol increased CB1 in DRG, reduced mechanical hyperalgesia and c-Fos expression in DRG and SC. Additionally, WIN 55,212-2 increased CB1 in DRG, reduced mechanical hyperalgesia, cold allodynia and c-Fos expression in DRG and SC. CB1 blockage hastened the cold allodynia response, but the CB2 antagonist failed to modulate the oxaliplatin-induced nociceptive behavior. Oxaliplatin also increased Iba-1 in DRG, suggesting immune response modulation which was reduced by cannabidiol and enhanced by AM630. The modulation of the endocannabinoid system, through the CB1 receptor, attenuates the oxaliplatin-associated PNS. The activation of the endocannabinoid system could be considered as a therapeutic target for controlling oxaliplatin-associated neuropathy.

 

Keywords: Cannabidiol, Cannabinoid receptors, Endocannabinoid system, Neuropathy, Oxaliplatin

References

    1. Argyriou AA (2015) Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics 3:187–197. https://doi.org/10.3390/toxics3020187 – DOI – PubMed – PMC
    1. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77. https://doi.org/10.1016/j.critrevonc.2011.04.012 – DOI – PubMed
    1. Branca JJV, Maresca M, Morucci G, Becatti M, Paternostro F, Gulisano M et al. (2018) Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity. Oncotarget 9:23426–23438. https://doi.org/10.18632/oncotarget.25193
    1. Calls A, Carozzi V, Navarro X, Monza L, Bruna J (2020) Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies. Exp Neurol. https://doi.org/10.1016/j.expneurol.2019.113141 – DOI – PubMed
    1. Cavaletti G, Marmiroli P (2020) Management of oxaliplatin-induced peripheral sensory neuropathy. Cancers (basel) 12:1370. https://doi.org/10.3390/cancers12061370 – DOI

Leave a Reply